295 related articles for article (PubMed ID: 27348464)
1. Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan.
Virabhak S; Yasui K; Yamazaki K; Johnson S; Mitchell D; Yuen C; Samp JC; Igarashi A
J Med Econ; 2016 Dec; 19(12):1144-1156. PubMed ID: 27348464
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection.
Johnson SJ; Parisé H; Virabhak S; Filipovic I; Samp JC; Misurski D
J Med Econ; 2016 Oct; 19(10):983-94. PubMed ID: 27172133
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
Saab S; Virabhak S; Parisé H; Johnson S; Wang A; Misurski D; Gonzalez YS; Juday T
Adv Ther; 2016 Aug; 33(8):1316-30. PubMed ID: 27342742
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
Saab S; Parisé H; Virabhak S; Wang A; Marx SE; Sanchez Gonzalez Y; Misurski D; Johnson S
J Med Econ; 2016 Aug; 19(8):795-805. PubMed ID: 27063573
[TBL] [Abstract][Full Text] [Related]
5. Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
Isakov V; Paduta D; Viani RM; Enejosa JV; Pasechnikov V; Znoyko O; Ogurtsov P; Bogomolov PO; Maevskaya MV; Chen X; Shulman NS
Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1073-1076. PubMed ID: 29762255
[TBL] [Abstract][Full Text] [Related]
6. Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients.
Abdel-Moneim A; Aboud A; Abdel-Gabbar M; Zanaty M; Ramadan M
Dig Dis Sci; 2018 May; 63(5):1341-1347. PubMed ID: 29546644
[TBL] [Abstract][Full Text] [Related]
7. Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.
Sato K; Chayama K; Alves K; Toyoda H; Suzuki F; Kato K; Rodrigues L; Zhang X; Setze C; Pilot-Matias T; Burroughs M; Redman R; Kumada H
Adv Ther; 2017 Jun; 34(6):1449-1465. PubMed ID: 28536999
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin Regimen for Patients Infected With Chronic Hepatitis C Virus Genotype 1 in Malaysia.
Shafie AA; Abu Hassan MR; Ong SC; Virabhak S; Gonzalez YS
Value Health Reg Issues; 2020 May; 21():164-171. PubMed ID: 31978690
[TBL] [Abstract][Full Text] [Related]
9. Combination Therapy with Ombitasvir/Paritaprevir/Ritonavir for Dialysis Patients Infected with Hepatitis C Virus: A Prospective Multi-Institutional Study.
Sato K; Hosonuma K; Yamazaki Y; Kobayashi T; Takakusagi S; Horiguchi N; Kakizaki S; Kusano M; Ohnishi H; Okamoto H; Yamada M
Tohoku J Exp Med; 2017 Jan; 241(1):45-53. PubMed ID: 28090038
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III).
Shafran SD; Shaw D; Charafeddine M; Agarwal K; Foster GR; Abunimeh M; Pilot-Matias T; Pothacamury RK; Fu B; Cohen E; Cohen DE; Gane E
J Viral Hepat; 2018 Feb; 25(2):118-125. PubMed ID: 28833938
[TBL] [Abstract][Full Text] [Related]
11. Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders.
Fuchs M; Monto A; Bräu N; Charafeddine M; Schmidt W; Kozal M; Naggie S; Cheung R; Schnell G; Yu Y; Richards K; Mullally V; Cohen DE; Toro D
J Med Virol; 2020 Dec; 92(12):3459-3464. PubMed ID: 31829433
[TBL] [Abstract][Full Text] [Related]
12. Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.
Ferenci P; Bourgeois S; Buggisch P; Norris S; Curescu M; Larrey D; Marra F; Kleine H; Dorr P; Charafeddine M; Crown E; Bondin M; Back D; Flisiak R
J Viral Hepat; 2019 Jun; 26(6):685-696. PubMed ID: 30739368
[TBL] [Abstract][Full Text] [Related]
13. Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy.
Poordad F; Bennett M; Sepe TE; Cohen E; Reindollar RW; Everson G; Phillips RW; Siddique A; Sullivan JG; Pilot-Matias T; Abunimeh M; Cohen DE; Younes Z
J Med Virol; 2019 Jul; 91(7):1307-1312. PubMed ID: 30840774
[TBL] [Abstract][Full Text] [Related]
14. The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1.
Miyasaka A; Yoshida Y; Yoshida T; Murakami A; Abe K; Ohuchi K; Kawakami T; Watanabe D; Hoshino T; Sawara K; Takikawa Y
Intern Med; 2018 Oct; 57(19):2807-2812. PubMed ID: 29780135
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
Lawitz E; Makara M; Akarca US; Thuluvath PJ; Preotescu LL; Varunok P; Morillas RM; Hall C; Mobashery N; Redman R; Pilot-Matias T; Vilchez RA; Hézode C
Gastroenterology; 2015 Oct; 149(4):971-80.e1. PubMed ID: 26170136
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.
Kumada H; Chayama K; Rodrigues L; Suzuki F; Ikeda K; Toyoda H; Sato K; Karino Y; Matsuzaki Y; Kioka K; Setze C; Pilot-Matias T; Patwardhan M; Vilchez RA; Burroughs M; Redman R
Hepatology; 2015 Oct; 62(4):1037-46. PubMed ID: 26147154
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
Dore GJ; Conway B; Luo Y; Janczewska E; Knysz B; Liu Y; Streinu-Cercel A; Caruntu FA; Curescu M; Skoien R; Ghesquiere W; Mazur W; Soza A; Fuster F; Greenbloom S; Motoc A; Arama V; Shaw D; Tornai I; Sasadeusz J; Dalgard O; Sullivan D; Liu X; Kapoor M; Campbell A; Podsadecki T
J Hepatol; 2016 Jan; 64(1):19-28. PubMed ID: 26321288
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan.
Igarashi A; Tang W; Guerra I; Marié L; Cure S; Lopresti M
Curr Med Res Opin; 2017 Jan; 33(1):11-21. PubMed ID: 27609424
[TBL] [Abstract][Full Text] [Related]
19. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
Tronina O; Durlik M; Wawrzynowicz-Syczewska M; Buivydiene A; Katzarov K; Kupcinskas L; Tolmane I; Karpińska E; Pisula A; Karwowska KM; Bolewska B; Jabłkowski M; Rostkowska K; Jakutiene J; Simonova M; Flisiak R
Ann Transplant; 2017 Apr; 22():199-207. PubMed ID: 28386057
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
Chayama K; Suzuki F; Karino Y; Kawakami Y; Sato K; Atarashi T; Naganuma A; Watanabe T; Eguchi Y; Yoshiji H; Seike M; Takei Y; Kato K; Alves K; Burroughs M; Redman R; Pugatch DL; Pilot-Matias TJ; Krishnan P; Oberoi RK; Xie W; Kumada H
J Gastroenterol; 2018 Apr; 53(4):557-565. PubMed ID: 28948366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]